Understanding SARS-CoV-2's viral strategies for infection

Acta Pharmaceutica Sinica BSep 26 2024

This new article publication from Acta Pharmaceutica Sinica B, discusses how SARS-CoV-2 ORF10 hijacking ubiquitination machinery reveals potential unique drug targeting sites.

Viruses often manipulate ubiquitination pathways to facilitate their replication and pathogenesis. CUL2^ZYG11B known as the substrate receptor of cullin-2 RING E3 ligase, is bound by SARS-CoV-2 ORF10 to increase its E3 ligase activity, leading to degradation of IFT46, a protein component of the intraflagellar transport (IFT) complex B. This results in dysfunctional cilia, which explains certain symptoms that are specific to COVID-19.

However, the precise molecular mechanism of how ORF10 recognizes CUL2^ZYG11B remains unknown. The authors of this article determined the crystal structure of CUL2^ZYG11B complexed with the N-terminal extension (NTE) of SARS-CoV-2 ORF10 (2.9 Å). The structure reveals that the ORF10 N-terminal heptapeptide (NTH) mimics the Gly/N-degron to bind CUL2^ZYG11B. Mutagenesis studies identified key residues within ORF10 that are key players in its interaction with CUL2^ZYG11B both in ITC assay and in vivo cells. In addition, enhancement of CUL2^ZYG11B activity for IFT46 degradation by which ORF10-mediated correlates with the binding affinity between ORF10 and CUL2^ZYG11B was proven. Finally, a Global Protein Stability system was used to show that the NTH of ORF10 mimics the Gly/N-degron motif, thereby binding competitively to CUL2^ZYG11B and inhibiting the degradation of target substrates bearing the Gly/N-degron motif.

Overall, this study sheds light on how SARS-CoV-2 ORF10 exploits the ubiquitination machinery for proteasomal degradation, and offers valuable insights for optimizing PROTAC-based drug design based on NTH CUL2^ZYG11B interaction, while pinpointing a promising target for the development of treatments for COVID-19.